Presentation to the LARTA (www.larta.org) NIH-CAP Workshop in November 2011 on how to develop FDA-regulated products, with a focus on planning, working with FDA,
According to new syllabus of PCI M.Pharm 1st sem. students can directly utilize this ppt for their study. As per PCI new syllabus QA STUDENTS find this ppt very use full.
Ensuring FDA Regulatory Success for Biomedical Companies -- Key Lessons for S...Michael Swit
Supporting Materials for Michael Swit's Panel remarks at the Workshop Co-sponsored by the Orange County Regulatory Affairs (OCRA) Discussion Group and the Small Business Development Center (SBDC) @ UCI Applied Innovation
REGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENTMichael Swit
Presentation to the Pharmaceutical Education Associates
"From Pipeline to Product: Navigating the FDA Approval Process" conference in Alexandria, VA, on November 30, 2007, with a focus on:
• Overall Planning
• Working With FDA
• Clinical Trial Execution
• CMC Issues
• Safety Issues
• Labeling
• Ingredients –Active And Inactive
According to new syllabus of PCI M.Pharm 1st sem. students can directly utilize this ppt for their study. As per PCI new syllabus QA STUDENTS find this ppt very use full.
Ensuring FDA Regulatory Success for Biomedical Companies -- Key Lessons for S...Michael Swit
Supporting Materials for Michael Swit's Panel remarks at the Workshop Co-sponsored by the Orange County Regulatory Affairs (OCRA) Discussion Group and the Small Business Development Center (SBDC) @ UCI Applied Innovation
REGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENTMichael Swit
Presentation to the Pharmaceutical Education Associates
"From Pipeline to Product: Navigating the FDA Approval Process" conference in Alexandria, VA, on November 30, 2007, with a focus on:
• Overall Planning
• Working With FDA
• Clinical Trial Execution
• CMC Issues
• Safety Issues
• Labeling
• Ingredients –Active And Inactive
Ensuring FDA Regulatory Success for Biomedical CompaniesMichael Swit
February 27, 2008 presentation to the Israeli Life Sciences Fellows of the Merage Foundation on product development issues, including:
* Overall Planning
* Working With FDA
* Clinical Trial Execution
* CMC and Design History Issues
* Safety Issues
* Labeling
* Ingredients –Active And Inactive; Component for Medical Devices
Drug Development in Today's Regulatory EnvironmentMichael Swit
Webinar sponsored by NanoTecNexus (www.http://nanotecnexus.org/) on contemporary regulatory issues in drug development, with an emphasis on:
Overall Planning
Working With FDA
Clinical Trial Execution
CMC Issues
Safety Issues
Labeling
Ingredients – Active And Inactive
REGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENTMichael Swit
Presentation to the San Diego Chapter of the American Chemical Society on on contemporary regulatory issues in drug development, with an emphasis on:
Overall Planning
Working With FDA
Clinical Trial Execution
CMC Issues
Safety Issues
Labeling
Ingredients – Active And Inactive
FDA Regulatory Considerations for the Biomedical CompaniesMichael Swit
Presentation to the LARTA (www.larta.org) NIH-CAP Workshop in October 2007 on how to develop FDA-regulated products, with a focus on planning, working with FDA, regulatory pitfalls, clinical studies, etc.
FDA Regulatory Considerations for the Biomedical Start-upMichael Swit
October 7, 2005 presentation to the LARTA CAP program in Newport Beach, CA, focusing on:
* 3 key roles of FDA
* tips for the unwary
* regulatory definitions
* submission types
* data required for approval
FDA Regulatory Considerations for Life Sciences CompaniesMichael Swit
April 2008 presentation to Swedish-American Chamber of Commerce Entrepreneurial Days on FDA issues for product development, including focus on:
Planning, approval process, barriers to entry
Regulatory, Quality & Clinical Due Diligence: The Oft Overlooked Keys to Suc...Michael Swit
June 23, 2010 webinar sponsored by The Weinberg Group, with an emphasis on key issues to explore during due diligence in acquiring FDA-regulated products or companies.
Successfully Responding to FDA Inspections (483s) & Warning LettersMichael Swit
November 10, 2015 webinar sponsored by Compliance2Go reviewing key issues and tactics associated with dealing with a company's reply to an FDA inspection and related warning letters. Includes lessons from actual responses.
FDA Legal & Regulatory Considerations for Biomedical StartupsMichael Swit
Presentation to the Tech Coast Angels on key legal and regulatory considerations for biomedical (drug and device) start-up companies, given on March 7, 2003.
The Small Company Clinical Study Sponsor -- Roles & Duties Vis-à-vis LiabilityMichael Swit
September 24, 2014 presentation to the Outsourcing in Clinical Trials: Southern California Conference, sponsored by Arena Conferences, focusing on:
* Clarifying exactly what you are responsible for and what you made be held accountable for
* Analyzing degrees of liability between bigger and smaller companies
* Ensuring that you are enforcing compliance from your outsourcing partners to avoid repercussions on yourselves
* Determining aspects of your trial management that you should retain in-house as a minimum so as to avoid liability issues
* Explaining to funders why quality and risk-assessments are a necessary expenditure above the cheapest options
Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...Yavuz Silay
Strategies for Conducting New Product Scientific Assessment - Due Diligence - New Strategies for Successful Licensing Acquisitions , DIA , Session Panel, June 22 2008,
FDA Enforcement: The Cop is Back – How Enhanced Enforcement Can Impact You a...Michael Swit
December 15, 2010 webinar sponsored by The Weinberg Group on increased FDA enforcement activity under the Obama administration, with a focus on:
Enforcement Trends Prior to Obama Administration
Commissioner Hamburg Revives FDA’s Compliance Culture –The August 6, 2009 Speech and its Impact
Key FDA Enforcement Actions
How to Prepare for Increased Enforcement
How to Respond if Targeted
Consequences of Non-Compliance
FDA’s Record under Enhanced Compliance
Regulatory & Quality Considerations in Virtual Drug DevelopmentMichael Swit
Presentation to Strategies for Success in Virtual Drug Development Conference on April 15, 2013, in San Diego, focusing on:
• General Considerations
• Why Quality & Regulatory Matter
• What Problems to Look For
• How to Find Problems
• Special Considerations
Similar to Regulatory Considerations in Product Development (20)
GMP Review -- Legal Letter from America Column -- How Data Integrity Issues S...Michael Swit
Article appearing in the October 2018 issue of GMP Review by Michael A. Swit explores how data integrity issues sunk a $4.3 billion acquisition of Akorn by Fresenius. Article stresses lessons not just for quality professionals, but also their top management.
FDA Regulation of Promotion & Advertising -- Part 8: Handling Promotional Com...Michael Swit
Presentation to the Compliance Online 2-day course on Ensuring Compliance with FDA Requirements for the Promotion & Advertising of Drugs and Medical Devices,November 2, 2018, Boston.
FDA Regulation of Promotion & Advertising -- Part 7: FTC RegulationMichael Swit
Presentation to the Compliance Online 2-day course on Ensuring Compliance with FDA Requirements for the Promotion & Advertising of Drugs and Medical Devices,
FDA Regulation of Promotion & Advertising -- Part 6: First Amendment, Off-Lab...Michael Swit
Presentation to the Compliance Online 2-day course on Ensuring Compliance with FDA Requirements for the Promotion & Advertising of Drugs and Medical Devices, November 2, 2018, Boston.
FDA Regulation of Promotion & Advertising -- Part 5: Social Media & InternetMichael Swit
Presentation to the Compliance Online 2-day course on Ensuring Compliance with FDA Requirements for the Promotion & Advertising of Drugs and Medical Devices, November 1-2, 2018, Boston
FDA Regulation of Promotion & Advertising -- Part 4: FDA Enforcement – Action...Michael Swit
Presentation to the Compliance Online 2-day course on Ensuring Compliance with FDA Requirements for the Promotion & Advertising of Drugs and Medical Devices, November 1-2, 2018, Boston.
FDA Regulation of Promotion & Advertising -- Part 3: Disseminating Scientific...Michael Swit
Presentation to the Compliance Online 2-day course on Ensuring Compliance with FDA Requirements for the Promotion & Advertising of Drugs and Medical Devices, November 1-2, 2018, Boston
FDA Regulation of Promotion & Advertising --Part 2: Direct-to-Consumer AdsMichael Swit
Presentation to the Compliance Online 2-day course on Ensuring Compliance with FDA Requirements for the Promotion & Advertising of Drugs and Medical Devices,November 1-2, 2018, Boston
FDA Regulation of Promotion & Advertising -- Part 1: The BasicsMichael Swit
Presentation to the Compliance Online 2-day course on Ensuring Compliance with FDA Requirements for the Promotion & Advertising of Drugs and Medical Devices, November 1-2, 2018, Boston.
Presentation on Critical Legal Issues Facing GMP ComplianceMichael Swit
August 27, 2018 Presentation to the 23rd Annual GMP by the Sea Conference in Cambridge, Maryland, focusing on the potential legal consequences faced by companies that violate FDA's requirements on Good Manufacturing Practices (GMPs) for drugs and biologics
Overview of FDA Drug Manufacturing RequirementsMichael Swit
Presentation on FDA Regulation of Drug Manufacturing to the Introduction to Drug Law Course sponsored by the Food & Drug Law Institute (FDLI) on July 25, 2018 in San Francisco.
Combination Products, Orphan Drugs, and OTC DrugsMichael Swit
Presentation to the San Diego Regulatory Affairs Network (SDRAN) Regulatory Affairs Certification (RAC) Exam review course on FDA regulation of combination products, orphan drugs, and OTC drugs.
Latest Developments in and the Future of the Regulatory Landscape for Approv...Michael Swit
Presentation on "Latest Developments in and the Future of the
Regulatory Landscape for Approving Treatments
for Orphan and Rare Diseases," given at the Orphan Drugs & Rare Diseases -- 2018 Americas West Coast Conference.
June 25, 2018. San Diego, CA.
June 14, 2018 presentation to the San Diego Regulatory Affairs Network (SDRAN) Regulatory Affairs Certification (RAC) Review Course on the basics of FDA regulation of generic drugs and biosimilars.
Recent FDA Developments in Digital Health & Clinical Decision Support SoftwareMichael Swit
June 7, 2018 presentation at the 4th Annual Medical Device Summit, sponsored by ComplianceOnline, in San Francisco, focusing on the impact of the 21st Century Cures Act and other developments on how FDA regulates software in the medical device arena, including mobile medical applications.
FDA Inspections: Handling the Consequences -- or Understanding How Ugly It C...Michael Swit
Presentation to the MAGI Clinical Research Conference – 2018 East, given on May 22, 2018 in Arlington, Virginia, and focusing on the collateral consequences of negative FDA inspections in the clinical research arena
Matthew Professional CV experienced Government LiaisonMattGardner52
As an experienced Government Liaison, I have demonstrated expertise in Corporate Governance. My skill set includes senior-level management in Contract Management, Legal Support, and Diplomatic Relations. I have also gained proficiency as a Corporate Liaison, utilizing my strong background in accounting, finance, and legal, with a Bachelor's degree (B.A.) from California State University. My Administrative Skills further strengthen my ability to contribute to the growth and success of any organization.
Car Accident Injury Do I Have a Case....Knowyourright
Every year, thousands of Minnesotans are injured in car accidents. These injuries can be severe – even life-changing. Under Minnesota law, you can pursue compensation through a personal injury lawsuit.
In 2020, the Ministry of Home Affairs established a committee led by Prof. (Dr.) Ranbir Singh, former Vice Chancellor of National Law University (NLU), Delhi. This committee was tasked with reviewing the three codes of criminal law. The primary objective of the committee was to propose comprehensive reforms to the country’s criminal laws in a manner that is both principled and effective.
The committee’s focus was on ensuring the safety and security of individuals, communities, and the nation as a whole. Throughout its deliberations, the committee aimed to uphold constitutional values such as justice, dignity, and the intrinsic value of each individual. Their goal was to recommend amendments to the criminal laws that align with these values and priorities.
Subsequently, in February, the committee successfully submitted its recommendations regarding amendments to the criminal law. These recommendations are intended to serve as a foundation for enhancing the current legal framework, promoting safety and security, and upholding the constitutional principles of justice, dignity, and the inherent worth of every individual.
NATURE, ORIGIN AND DEVELOPMENT OF INTERNATIONAL LAW.pptxanvithaav
These slides helps the student of international law to understand what is the nature of international law? and how international law was originated and developed?.
The slides was well structured along with the highlighted points for better understanding .
A "File Trademark" is a legal term referring to the registration of a unique symbol, logo, or name used to identify and distinguish products or services. This process provides legal protection, granting exclusive rights to the trademark owner, and helps prevent unauthorized use by competitors.
Visit Now: https://www.tumblr.com/trademark-quick/751620857551634432/ensure-legal-protection-file-your-trademark-with?source=share
ALL EYES ON RAFAH BUT WHY Explain more.pdf46adnanshahzad
All eyes on Rafah: But why?. The Rafah border crossing, a crucial point between Egypt and the Gaza Strip, often finds itself at the center of global attention. As we explore the significance of Rafah, we’ll uncover why all eyes are on Rafah and the complexities surrounding this pivotal region.
INTRODUCTION
What makes Rafah so significant that it captures global attention? The phrase ‘All eyes are on Rafah’ resonates not just with those in the region but with people worldwide who recognize its strategic, humanitarian, and political importance. In this guide, we will delve into the factors that make Rafah a focal point for international interest, examining its historical context, humanitarian challenges, and political dimensions.
How to Obtain Permanent Residency in the NetherlandsBridgeWest.eu
You can rely on our assistance if you are ready to apply for permanent residency. Find out more at: https://immigration-netherlands.com/obtain-a-permanent-residence-permit-in-the-netherlands/.
Synopsis On Annual General Meeting/Extra Ordinary General Meeting With Ordinary And Special Businesses And Ordinary And Special Resolutions with Companies (Postal Ballot) Regulations, 2018
Responsibilities of the office bearers while registering multi-state cooperat...Finlaw Consultancy Pvt Ltd
Introduction-
The process of register multi-state cooperative society in India is governed by the Multi-State Co-operative Societies Act, 2002. This process requires the office bearers to undertake several crucial responsibilities to ensure compliance with legal and regulatory frameworks. The key office bearers typically include the President, Secretary, and Treasurer, along with other elected members of the managing committee. Their responsibilities encompass administrative, legal, and financial duties essential for the successful registration and operation of the society.
Responsibilities of the office bearers while registering multi-state cooperat...
Regulatory Considerations in Product Development
1. FDACounsel.com
FDA Legal Services -- for the life of a Life Sciences Company
FDACounsel.com
FDA Legal Services -- for the life of a Life Sciences Company
Regulatory Considerations in
Product Development
Michael A. Swit, Esq.
November 1, 2011
LARTA NIH-CAP Workshop
2. FDACounsel.com
FDA Legal Services -- for the life of a Life Sciences Company
Disclaimers
• This outline is intended to support an oral
briefing and should not be relied upon solely
to support any conclusion of fact or law.
• The views reflected in this presentation are
solely those of the presenter and do not
necessarily reflect the position of my firm,
any of its clients, or any of my friends and
colleagues that contributed their thoughts to
this presentation.
2
3. FDACounsel.com
FDA Legal Services -- for the life of a Life Sciences Company
FDACounsel.com
FDA Legal Services -- for the life of a Life Sciences Company
Establish FDA Strategy Early!!
Some considerations follow . . .
4. FDACounsel.com
FDA Legal Services -- for the life of a Life Sciences Company
REGULATORY PLANNING
• Create A Project Plan With Well-defined
Go/No-go Decision Points –
– Difficult, But Vital To Know When To Shift
Gears.
– Plan With The End In Mind – your ultimate
labeling will drive what you need to do – create a
“Product Profile” early and try to stick to it.
4
5. FDACounsel.com
FDA Legal Services -- for the life of a Life Sciences Company
PLANNING …
• Make Sure You Are Ready To Go From “R" to “D"
– Internally - people and systems; change in mindset from
research to development.
– Drug Formulation or Device Design Has Been
Rigorously Reviewed -- so as to optimize your chances
when going into humans.
• Device – needs design controls under QSR regulations
– Once Clinical Evaluation Begins, Preclinical Efficacy
Experiments -- should be limited or undergo rigorous
review and oversight.
– Educate Scientists And Researchers – on the realities of
the demands of development, especially documentation
• Example -- report writing -- may be a weakness in research, but is important in
development. Start early in the process.
5
6. FDACounsel.com
FDA Legal Services -- for the life of a Life Sciences Company
PLANNING …
• Make Sure Regulatory, Clinical, And Sales &
Marketing Are All Talking Early On –
– Ensure Indication or Intended Use (thus,
Endpoints) Being Studied Is One You Want To Sell
– Some Consideration
• Study Design –while marketing may want superiority if you go for that
sort of study and fail, the FDA won’t let you reanalyze the study for
non-inferiority -- hence failed development program…
• Indication Choice – consider limited initial indication that can be the
starting point for subsequent bigger indications
– can be key to optimal product lifecycle management
6
7. FDACounsel.com
FDA Legal Services -- for the life of a Life Sciences Company
PLANNING …
• Beware of "Divergent Evolution" between
Product Development and Intellectual Property
Efforts!
– How Patents Can Evolve
• Attaining patent protection for a novel chemical entity or formulation is a
multiyear process,
• In process, claims often become more limited in number and in scope,
due to prior art, Patent Examiner concerns, etc
– Ensure A Strategic Linkage Between The Product
Development And Patenting Efforts -- to best
assure:
• Patent(s) granted actually cover critical features of the product being
studied in clinicals
• Clinicals actually cover patented/able claims
7
8. FDACounsel.com
FDA Legal Services -- for the life of a Life Sciences Company
PLANNING …
• Understand Approval Is Not Enough,
Somebody Has to Pay for It!! - coverage (on
formulary) and reimbursement (at a
reasonable copay tier).
– Some keys:
• Label claims -- Is there anything novel you can say?
• Comparative effectiveness:
–future of reimbursement
–future for competitive/comparative claims –
clinicals will be needed (FDA/FTC)
8
9. FDACounsel.com
FDA Legal Services -- for the life of a Life Sciences Company
PLANNING …
• Other Key Planning Efforts
– Product Name –
• Globalize the product name (be careful with different meanings)
• Seek regulatory agency concurrence early.
– Find Collateral Support; e.g., Patient Groups,
Thought Leaders
• can help with identifying investigators
• can help with patient recruitment
– Identify Enemies -- commercial and otherwise
(e.g., special interest groups)
• Anticipate their moves (e.g., Citizen Petitions)
– Pediatric Assessments -- -need a plan to address
pediatric usage if a drug or biologic
9
10. FDACounsel.com
FDA Legal Services -- for the life of a Life Sciences Company
PLANNING …
• Management
– Must Understand Process.
– Must Support Company's Quality System,
Especially As A Company Matures.
– Don’t Let Financial Milestones Drive
Development – recipe for disaster (e.g., Refuse To
Files, Clinical Holds).
– Contrast:
“What is the minimum we need to do to get approval?"
vs.
"What is necessary for us to provide in order to get a first cycle
review approval".
[if your CEO thinks first option is OK, time to update your CV]
10
11. FDACounsel.com
FDA Legal Services -- for the life of a Life Sciences Company
WORKING WITH FDA
• Early interaction -- essential to understanding
your path and what you need in your kitbag
– FDA encourages and appreciates (usually) being
consulted early in the development stage -- helps build a
relationship with Agency that can pay off during the
approval process.
– Take advantage of all Regulatory “value-added”
initiatives – e.g., on drug side, Fast Track, Accelerated
Approval, Orphan Drug, Special Protocol Assessment
(but be careful on this)
11
12. FDACounsel.com
FDA Legal Services -- for the life of a Life Sciences Company
WORKING WITH FDA …
• Ensure You Get Agency Agreement On Exactly What Is The
Indication – will drive related labeling language, especially if
related to disease, treatment or metrics
– Example: “Chronic sinusitis”
• Not in DSM or accepted text books -- really a term of art among ENTs.
• Company
– started clinical trials,
– Then, went to FDA – “we’re treating chronic sinusitis!!”
• FDA -- “what’s’ that?” -- leading to a rather lengthy debate about
symptomatology of “chronic sinusitis”.
• Result – company had already studied something not entirely covered by
the now agreed upon definition of “chronic sinusitis” both as to:
– outcomes
– method of measuring
• Consequence – also can end up proving a labeled indication that does
not jibe with original marketing projections
12
13. FDACounsel.com
FDA Legal Services -- for the life of a Life Sciences Company
WORKING WITH FDA …
• Safety is Lynchpin Today –
– Focus On Signals/AE’s Early
• Ensure personnel evaluating are qualified
– “REMS” –
• “Risk Evaluation and Mitigation Strategies”
• Future is now – due to Food & Drug Administration
Amendments Act of 2007 –
• You need to control REMS process; don’t let FDA
– Example: anticipate Phase IV, Post-Approval Study, but drive
its design
13
14. FDACounsel.com
FDA Legal Services -- for the life of a Life Sciences Company
WORKING WITH FDA …
• Listen!!
– If You Get Regulatory Agency Advice -- Do It!
(well, almost all the time)
• Failure to adhere to any given advice may only subsequently
antagonize the reviewer.
• Caveat -- If you don’t want to do it or think it’s wrong, engage FDA
promptly to gain its buy-in to your position
– Don’t just ignore FDA and go down your own path
• Keep your Promises!!
– A sure way to lose credibility – fail to deliver what
you promised
14
16. FDACounsel.com
FDA Legal Services -- for the life of a Life Sciences Company
• What is the likelihood that the FDA will require
a companion test for targeted therapies?
• Discuss value of early, informal meetings with
FDA.
• Discuss orphan drug status, and what it means
regarding FDA approval.
• What are the best strategies for obtaining FDA
approval, alone or with partner or through help
in NIH funding?
Regulatory Questions
16
17. FDACounsel.com
FDA Legal Services -- for the life of a Life Sciences Company
• In cancer diagnostics, does a service (e.g.
detection of cancer cells in patients, chemo-
sensitivity testing, selection of therapeutic
agents using patient’s cancer cells etc..) to
oncologists or physicians for their treatment
decision-making require an approval by the
FDA? If so, how to obtain such approval
(not for FDA clearance – 510k or approval –
premarket application)?
Regulatory Questions …
17
18. FDACounsel.com
FDA Legal Services -- for the life of a Life Sciences Company
• How do you achieve “buy-in” from hospitals
or other customers to achieve
reimbursement for a medical device? i.e. the
device has been tested and proven in a lab-
setting (say reduce bacteria in-vitro), but full
data on the cost-savings to a hospital
(reduce infections) is not fully proven.
• Navigating the FDA vs other routes (i.e.
achieving approval in Europe first)
Regulatory Questions …
18
19. FDACounsel.com
FDA Legal Services -- for the life of a Life Sciences Company
FDACounsel.com
Call, e-mail, fax or write:
Michael A. Swit, Esq.
Founder, FDACounsel.com
1422 Caminito Septimo
Cardiff by the Sea, CA 92007
Phone 760.452.6568
Fax 760.454.2979
Cell 760.815.4762
mswit@fdacounsel.com
Questions after the Conference?
19
20. FDACounsel.com
FDA Legal Services -- for the life of a Life Sciences Company
About your Speaker …
Michael A. Swit, Esq. develops and ensures the execution of a broad array of regulatory and other services to his
clients. His expertise includes regulated product development strategies, compliance and enforcement initiatives,
recalls and crisis management, submissions and related traditional FDA regulatory activities, labeling and
advertising, and clinical research efforts for drug, biologic, device, IVD, and other life sciences companies, as well
as those in the food and dietary supplement industries.
Mr. Swit has been addressing critical FDA legal and regulatory issues since 1984. His vast and multi-faceted
experience includes serving for three and a half years as corporate vice president, general counsel and secretary of
Par Pharmaceutical, a prominent, publicly-traded, generic drug company and, thus, he brings an industry and
commercial perspective to his work with FDA-regulated companies. Mr. Swit then served for over four years as
CEO of FDANews.com, a premier publisher of FDA regulatory newsletters and other specialty information products
for the FDA-regulated community. His private FDA regulatory law practice has included service as Special Counsel
in the FDA Law Practice Group in the San Diego office of Heller Ehrman White & McAuliffe and with the Food &
Drug Law practice at McKenna & Cuneo, both in the firm’s Washington office and later in San Diego. He first
practiced FDA regulatory law with the D.C. office of Burditt & Radzius.
Mr. Swit has taught and written on a wide variety of subjects relating to FDA law, regulation and related commercial
activities, including, since 1989, co-directing a three-day intensive course on the generic drug approval process and
editing a guide to the generic drug approval process, Getting Your Generic Drug Approved. A former member of the
Food & Drug Law Journal Editorial Board, he also has been a prominent speaker at numerous conferences
sponsored by such organizations as RAPS, FDLI, and DIA. He received his A.B., magna cum laude, with high
honors in History, from Bowdoin College and his law degree from Emory University School of Law. Mr. Swit is a
member of the California Bar.
20